A multi-center, randomized, double-blind, parallel-group study evaluating the sexual functioning of healthy adults after receiving multiple-dose regimens of vilazodone, paroxetine, or placebo

Trial Profile

A multi-center, randomized, double-blind, parallel-group study evaluating the sexual functioning of healthy adults after receiving multiple-dose regimens of vilazodone, paroxetine, or placebo

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Vilazodone (Primary) ; Paroxetine
  • Indications Generalised anxiety disorder; Major depressive disorder; Sexual function disorders; Social phobia
  • Focus Therapeutic Use
  • Sponsors Actavis; Forest Laboratories
  • Most Recent Events

    • 16 Sep 2016 Results published in the International Clinical Psychopharmacology
    • 11 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Jul 2014 According to Actavis media release, Forest Laboratories was acquired by Actavis in Jul 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top